ADC Therapeutics Ownership | Who Owns ADC Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

ADC Therapeutics Ownership Summary

ADC Therapeutics is owned by 1.79% institutional investors, 13.76% insiders, and 84.45% retail investors. Redmile group is the largest institutional shareholder, holding 13.77% of ADCT shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 2.68% of its assets in ADC Therapeutics shares.

ADCT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	ADC Therapeutics	1.79%	13.76%	84.45%
Sector	Healthcare Stocks	232.64%	10.66%	-143.30%
Industry	Biotech Stocks	382.13%	10.41%	-292.54%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Redmile group	15.67M	13.77%	$62.67M
Point72 asset management	8.14M	7.15%	$32.54M
Prosight management, lp	8.48M	6.21%	$29.93M
Orbimed advisors	5.91M	5.19%	$23.63M
Blackrock	3.55M	4.31%	$11.23M
Nantahala capital management	5.48M	4.01%	$19.33M
Blackrock funding, inc. /de	5.43M	3.98%	$19.16M
Morgan stanley	3.77M	2.76%	$13.31M
Bank of america corp /de/	1.22M	1.47%	$3.84M
Artal group	1.02M	1.23%	$3.22M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Vantage consulting group	683.00K	12.23%	$2.41M
Prosight management, lp	8.48M	6.18%	$29.93M
Redmile group	15.67M	6.10%	$62.67M
Lynx1 capital management lp	1.33M	1.08%	$5.30M
Nantahala capital management	5.48M	0.64%	$19.33M
Orbimed advisors	5.91M	0.56%	$23.63M
Opaleye management	682.53K	0.39%	$2.73M
Heights capital management	326.77K	0.36%	$1.31M
Platinum investment management	1.16M	0.30%	$4.63M
Tcg crossover management	1.39M	0.27%	$5.56M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	3.55M	0.00%	3.55M
Nantahala capital management	5.48M	0.64%	3.21M
Tcg crossover management	1.39M	0.27%	1.39M
Lynx1 capital management lp	1.33M	1.08%	1.33M
Artal group	1.02M	0.08%	1.02M

Top Sellers

Holder	Shares	% Assets	Change
Heights capital management	326.77K	0.36%	-2.51M
Silverarc capital management	-	-	-1.80M
Siren	-	-	-1.16M
Adage capital partners gp	-	-	-1.00M
Woodline partners lp	-	-	-842.90K

New Positions

Holder	Shares	% Assets	Change	Value
Blackrock	3.55M	0.00%	3.55M	$11.23M
Tcg crossover management	1.39M	0.27%	1.39M	$5.56M
Lynx1 capital management lp	1.33M	1.08%	1.33M	$5.30M
Artal group	1.02M	0.08%	1.02M	$3.22M
Opaleye management	682.53K	0.39%	682.53K	$2.73M

Sold Out

Holder	Change
Clearstead advisors	-1.00
Gradient investments	-11.00
Federation des caisses desjardins du quebec	-20.00
Northwestern mutual wealth management	-36.00
Southstate	-46.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	20	-81.31%	2,443,188	-96.40%	1	0.05%	12	-77.78%	3	-86.96%
Sep 30, 2025	29	-67.78%	2,438,452	-96.43%	2	0.05%	10	-67.74%	7	-82.50%
Jun 30, 2025	90	8.43%	68,312,257	26.51%	63	2.51%	31	-20.51%	40	81.82%
Mar 31, 2025	84	-2.33%	54,846,273	-2.92%	51	1.76%	39	-20.41%	22	37.50%
Dec 31, 2024	86	8.86%	56,494,277	2.93%	53	1.97%	49	-5.77%	16	45.45%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Eventide Healthcare & Life Sciences I	3.36M	2.68%	3.36M
iShares Russell 2000 ETF	2.44M	1.92%	-19.93K
Biotech Growth Ord	1.88M	1.48%	-18.12K
Fidelity Small Cap Index	833.86K	0.66%	-11.77K
iShares Russell 2000 Growth ETF	830.09K	0.65%	-
iShares Biotechnology ETF	674.54K	0.53%	1.40K
State St Russell Sm/Mid Cp® Indx SL Cl I	608.04K	0.48%	93.30K
State St Russell Sm/Mid Cp® Indx NL Cl C	401.24K	0.40%	-
Vanguard Russell 2000 ETF	426.55K	0.34%	16.38K
International Biotechnology Ord	418.78K	0.33%	418.78K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Apr 01, 2026	Redmile Group, LLC	-	Sell	$617.40K
Mar 31, 2026	Redmile Group, LLC	-	Sell	$706.90K
Mar 31, 2026	Redmile Group, LLC	-	Sell	$736.25K
Apr 01, 2026	Redmile Group, LLC	-	Sell	$643.04K
Apr 02, 2026	Redmile Group, LLC	-	Sell	$8.64M

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	4
2026 Q1	-	2
2025 Q4	1	-
2025 Q2	2	-
2025 Q1	-	-

ADCT Ownership FAQ

Who Owns ADC Therapeutics?

ADC Therapeutics shareholders are primarily institutional investors at 1.79%, followed by 13.76% insiders and 84.45% retail investors. The average institutional ownership in ADC Therapeutics's industry, Biotech Stocks , is 382.13%, which ADC Therapeutics falls below.

Who owns the most shares of ADC Therapeutics?

ADC Therapeutics’s largest shareholders are Redmile group (15.67M shares, 13.77%), Point72 asset management (8.14M shares, 7.15%), and Prosight management, lp (8.48M shares, 6.21%). Together, they hold 27.14% of ADC Therapeutics’s total shares outstanding.

Does Blackrock own ADC Therapeutics?

Yes, BlackRock owns 4.31% of ADC Therapeutics, totaling 3.55M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 11.23M$. In the last quarter, BlackRock increased its holdings by 3.55M shares, a 100.00% change.

Who is ADC Therapeutics’s biggest shareholder by percentage of total assets invested?

Vantage consulting group is ADC Therapeutics’s biggest shareholder by percentage of total assets invested, with 12.23% of its assets in 683K ADC Therapeutics shares, valued at 2.41M$.

Who is the top mutual fund holder of ADC Therapeutics shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of ADC Therapeutics shares, with 2.68% of its total shares outstanding invested in 3.36M ADC Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools